Review summary
Teaching objective: Recognize ovarian cancer early in a woman of 39 with persistent bloating, early fullness, and pelvic pain, the symptoms that went unexplained for ten months in Gilda Radner's life: apply the ovarian cancer symptom index (Goff), examine the abdomen and pelvis, and order a CA-125 and a transvaginal ultrasound at the first visit; CT staging and an image-guided biopsy within the week; prompt gynecologic oncology care with primary cytoreductive surgery aiming for no visible residual disease; carboplatin and paclitaxel with antiemetic, neuropathy and blood-count monitoring and extended thromboprophylaxis; germline genetic counseling and testing for every woman with epithelial ovarian cancer, with tumor testing for BRCA1 and BRCA2; PARP inhibitor maintenance chosen from the tumor result; and survivorship care with distress screening and peer support, on the NCCN ovarian cancer guideline, the ASCO germline and somatic testing and PARP inhibitor guidelines, and ACOG Committee Opinion 716.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| June 28, 1946 | Born in Detroit, Michigan. | CLM-0001 |
| About 1960 (age 14) | Her father dies of brain cancer. | CLM-0003 |
| 1975 to 1980 | Original cast member of Saturday Night Live; bouts of bulimia in these years. | CLM-0002, CLM-0008 |
| September 1984 | Marries Gene Wilder; they try to have a child. | CLM-0002, CLM-0007 |
| 1985 to early 1986 | Severe fatigue begins and is attributed to Epstein-Barr virus. | CLM-0004 |
| October 1986 | After about ten months of bloating, pain and wrong diagnoses, diagnosed with stage IV ovarian cancer; surgery, then chemotherapy and radiation therapy. | CLM-0005, CLM-0006 |
| December 1988 | The cancer returns after a remission. | CLM-0009 |
| 1989 | Publishes It's Always Something. | CLM-0009 |
| May 20, 1989 | Dies at Cedars-Sinai Medical Center, Los Angeles, at 42. | CLM-0001, CLM-0010 |
| 1990 onward | Her husband speaks about the delay in her diagnosis; registry, detection center and Gilda's Club founded in her name. | CLM-0011, CLM-0012 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Gilda Radner was born on June 28, 1946, into a prosperous Detroit Jewish family; her paternal grandfather had emigrated from Lithuania. | confirmed | Most A. Gilda Radner. The Shalvi/Hyman Encyclopedia of Jewish Women supports Death of comedian Gilda Radner at 42 (This Week in History) supports |
| D | She was the first person cast in Saturday Night Live, performed with its original troupe from 1975 to 1980, won an Emmy Award in 1978, and made several films, including three with Gene Wilder, whom she married in 1984. Her work as a comedian and actor anchors the modern social history. |
confirmed | Most A. Gilda Radner. The Shalvi/Hyman Encyclopedia of Jewish Women supports |
| D | Her father died of brain cancer when she was fourteen. Her grandmother, a cousin, and an aunt had all had ovarian cancer. Family history only. A strong family history of ovarian cancer is the reason the modern episode offers germline testing at diagnosis. |
confirmed | Most A. Gilda Radner. The Shalvi/Hyman Encyclopedia of Jewish Women supports Micheli R. Inside Gene Wilder and Gilda Radner's Romance (excerpted from LIFE: Gene Wilder 1933-2016) supports Gilda Radner context |
| D | Her illness began with severe fatigue, which sources date to the filming of Haunted Honeymoon in England in 1985 or to early 1986; her internist attributed it to Epstein-Barr virus and told her not to worry. The start of the ten months of symptoms before her diagnosis; the anchor for the presenting problem in the modern episode. |
confirmed | Micheli R. Inside Gene Wilder and Gilda Radner's Romance (excerpted from LIFE: Gene Wilder 1933-2016) supports Gilda Radner supports Zakarin J. Gilda Radner and Gene Wilder's Enduring, and Heartbreaking, Love Story supports |
| D | Over the following months she had bloating so marked that she could barely button her trousers, cramps and pelvic pain, fevers, and shaking legs; one doctor thought it was depression and another constipation, and gynecologists said the cramps were nothing to worry about. In her memoir she wrote that she now had 'Epstein-Barr virus and mittelschmerz.' It was ten months from her first symptoms before ovarian cancer was found, and the CA-125 blood test was never done. The diagnostic delay that the modern episode teaches against: persistent bloating, pelvic pain and early satiety in a woman of 40 meet the ovarian cancer symptom index and call for a pelvic examination, a transvaginal ultrasound and a CA-125. |
confirmed | Zakarin J. Gilda Radner and Gene Wilder's Enduring, and Heartbreaking, Love Story supports Blevins J. Read This: Gilda Radner's needless death became Gene Wilder's crusade supports Micheli R. Inside Gene Wilder and Gilda Radner's Romance (excerpted from LIFE: Gene Wilder 1933-2016) supports Fuster J. Read Gene Wilder's Heartbreaking Essay About Wife Gilda Radner's Death supports |
| D | She was diagnosed with stage IV ovarian cancer in October 1986; surgery removed a tumor the size of a grapefruit, and chemotherapy and radiation therapy followed. The documented disease to which the synthetic diagnosis is linked. The stage and treatment in the modern episode are synthetic. |
confirmed | Our History supports Micheli R. Inside Gene Wilder and Gilda Radner's Romance (excerpted from LIFE: Gene Wilder 1933-2016) supports Gilda Radner supports Zakarin J. Gilda Radner and Gene Wilder's Enduring, and Heartbreaking, Love Story supports |
| D | Before her illness she and her husband tried to have a child; she had two miscarriages, one during the filming of Haunted Honeymoon in London, and an unsuccessful round of in vitro fertilization, after which doctors told her she was infertile. Reproductive history; not having carried a pregnancy is a recognized risk factor for ovarian cancer. History only. |
confirmed | Zakarin J. Gilda Radner and Gene Wilder's Enduring, and Heartbreaking, Love Story supports |
| D | During her Saturday Night Live years her lifelong insecurity about her appearance resurfaced in bouts of bulimia, which she later wrote about. History only. It is not coded and is not carried into the modern episode as a current diagnosis. |
confirmed | Most A. Gilda Radner. The Shalvi/Hyman Encyclopedia of Jewish Women supports Gilda Radner context |
| D | During treatment she found emotional support at The Wellness Community, through the psychotherapist Joanna Bull, and wrote her autobiography, It's Always Something, between chemotherapy treatments; it was published in 1989. After a remission, her cancer returned in December 1988. Support during treatment is part of the modern survivorship plan. |
confirmed | Most A. Gilda Radner. The Shalvi/Hyman Encyclopedia of Jewish Women supports Our History supports Gilda Radner supports |
| D | In May 1989 she was admitted to Cedars-Sinai Medical Center in Los Angeles for a CT scan, did not regain consciousness after sedation, and died there three days later, on May 20, 1989, at 42. History only, stated without detail. |
confirmed | Gilda Radner supports Micheli R. Inside Gene Wilder and Gilda Radner's Romance (excerpted from LIFE: Gene Wilder 1933-2016) supports Death of comedian Gilda Radner at 42 (This Week in History) supports Most A. Gilda Radner. The Shalvi/Hyman Encyclopedia of Jewish Women supports |
| D | After her death, Gilda's Club was founded in her honor by Gene Wilder, Joanna Bull and Joel Siegel, with the first clubhouse opening in 1995; it later merged with The Wellness Community to form the Cancer Support Community. Wilder testified to a House subcommittee about ovarian cancer, a detection center at Cedars-Sinai was named for her, and in 1990 the familial ovarian cancer registry at Roswell Park was named for her. Her legacy in early detection, hereditary risk and cancer support, which the modern episode reflects. |
confirmed | Our History supports Micheli R. Inside Gene Wilder and Gilda Radner's Romance (excerpted from LIFE: Gene Wilder 1933-2016) supports About the Familial Ovarian Cancer Registry supports Fuster J. Read Gene Wilder's Heartbreaking Essay About Wife Gilda Radner's Death supports |
| R | After her death her husband said that no doctor had asked about her family history of ovarian cancer, and wrote that her cancer might have been caught in time if her doctors had given her the CA-125 blood test or asked about that history, and that she 'didn't have to die.' A retrospective, personal reading after her death; whether earlier diagnosis would have changed the outcome cannot be known. The teaching point rests on the delay itself. |
possible | Micheli R. Inside Gene Wilder and Gilda Radner's Romance (excerpted from LIFE: Gene Wilder 1933-2016) supports Fuster J. Read Gene Wilder's Heartbreaking Essay About Wife Gilda Radner's Death supports Blevins J. Read This: Gilda Radner's needless death became Gene Wilder's crusade supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Persistent bloating with tightness of her clothes, feeling full after a few bites, a dull lower abdominal and pelvic ache, and passing urine more often, on most days for about four weeks, in a woman of 39: the ovarian cancer symptom index is positive. Examination: a distended abdomen with shifting dullness and a firm, fixed, irregular mass in the right adnexa. Suspected ovarian cancer; transvaginal ultrasound, CT, CA-125 and gynecologic oncology review booked within the week | resolved | confirmed | active | CLM-0004 |
| S | High-grade serous carcinoma of both ovaries (Mullerian origin), diagnosed by image-guided omental core biopsy (PAX8 and WT1 positive, p53 aberrant), with bilateral adnexal masses, ascites, omental and diaphragmatic disease on CT: clinical FIGO stage IIIC; synthetic modern detail linked to her documented ovarian cancer | active | confirmed | both_with_link | CLM-0005, CLM-0006 |
| S | Peritoneal and omental metastases of the ovarian cancer, with ascites | active | confirmed | active | CLM-0005, CLM-0006 |
| S | Family history of ovarian cancer in three relatives (her grandmother, an aunt, and a cousin) in a woman of Ashkenazi Jewish ancestry; no genetic testing in the family is known | active | confirmed | active | CLM-0003 |
| S | Acute viral upper respiratory infection on day 8 of the second chemotherapy cycle: two days of sore throat, runny nose and a dry cough, without fever; rapid influenza and COVID-19 tests negative; resolved | resolved | confirmed | active | |
| S | Symptomatic surgical menopause after bilateral salpingo-oophorectomy at 39: hot flashes and night sweats | active | confirmed | active | |
| S | Chemotherapy-induced peripheral neuropathy from paclitaxel: tingling in the toes and fingertips, grade 1 (sensory only, no effect on daily activities) | active | confirmed | active |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2026-04-06 | Hemoglobin [Mass/volume] in Blood | 12.4 g/dL Reference 11.6-15 g/dL |
http://loinc.org · 718-7 |
| S | 2026-04-06 | Leukocytes [#/volume] in Blood by Automated count | 7.8 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-04-06 | Platelets [#/volume] in Blood by Automated count | 412 10*3/uL (high) Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-04-06 | Sodium [Moles/volume] in Serum or Plasma | 136 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-04-06 | Potassium [Moles/volume] in Serum or Plasma | 4.2 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-04-06 | Creatinine [Mass/volume] in Serum or Plasma | 0.72 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-04-06 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 109 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-04-06 | Glucose [Mass/volume] in Serum or Plasma | 88 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-04-06 | Calcium [Mass/volume] in Serum or Plasma | 9.4 mg/dL Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 2026-04-06 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 2026-04-06 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 U/L Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 2026-04-06 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 84 U/L Reference 35-105 U/L |
http://loinc.org · 6768-6 |
| S | 2026-04-06 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2026-04-06 | Albumin [Mass/volume] in Serum or Plasma | 3.6 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 2026-04-06 | Cancer Ag 125 [Units/volume] in Serum or Plasma | 1240 U/mL (high) Reference <=35 U/mL |
http://loinc.org · 10334-1 |
| S | 2026-04-06 | Carcinoembryonic Ag [Mass/volume] in Serum or Plasma | 1.6 ng/mL Reference <=3 ng/mL |
http://loinc.org · 2039-6 |
| S | 2026-04-06 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | http://loinc.org · 55758-7 |
| S | 2026-04-06 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 5 | http://loinc.org · 72514-3 |
| S | 2026-04-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | http://loinc.org · 44261-6 |
| S | 2026-04-14 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 8 | http://loinc.org · 70274-6 |
| S | 2026-05-12 | Hemoglobin [Mass/volume] in Blood | 10.9 g/dL (low) Reference 11.6-15 g/dL |
http://loinc.org · 718-7 |
| S | 2026-05-12 | Leukocytes [#/volume] in Blood by Automated count | 6.9 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-05-12 | Neutrophils [#/volume] in Blood by Automated count | 4.2 10*3/uL Reference 1.5-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 2026-05-12 | Platelets [#/volume] in Blood by Automated count | 356 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-05-12 | Creatinine [Mass/volume] in Serum or Plasma | 0.68 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-05-12 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 114 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-05-12 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 2026-05-12 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 U/L Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 2026-05-12 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.4 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2026-05-12 | Albumin [Mass/volume] in Serum or Plasma | 3.7 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 2026-05-12 | Magnesium [Mass/volume] in Serum or Plasma | 1.9 mg/dL Reference 1.7-2.2 mg/dL |
http://loinc.org · 19123-9 |
| S | 2026-05-12 | Cancer Ag 125 [Units/volume] in Serum or Plasma | 188 U/mL (high) Reference <=35 U/mL |
http://loinc.org · 10334-1 |
| S | 2026-05-12 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | http://loinc.org · 44261-6 |
| S | 2026-05-12 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 2 | http://loinc.org · 72514-3 |
| S | 2026-06-09 | Hemoglobin [Mass/volume] in Blood | 10.6 g/dL (low) Reference 11.6-15 g/dL |
http://loinc.org · 718-7 |
| S | 2026-06-09 | Leukocytes [#/volume] in Blood by Automated count | 2.9 10*3/uL (low) Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-06-09 | Neutrophils [#/volume] in Blood by Automated count | 1.3 10*3/uL (low) Reference 1.5-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 2026-06-09 | Platelets [#/volume] in Blood by Automated count | 142 10*3/uL (low) Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-07-14 | Hemoglobin [Mass/volume] in Blood | 10.3 g/dL (low) Reference 11.6-15 g/dL |
http://loinc.org · 718-7 |
| S | 2026-07-14 | Leukocytes [#/volume] in Blood by Automated count | 4.1 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-07-14 | Neutrophils [#/volume] in Blood by Automated count | 1.9 10*3/uL Reference 1.5-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 2026-07-14 | Platelets [#/volume] in Blood by Automated count | 188 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-07-14 | Creatinine [Mass/volume] in Serum or Plasma | 0.7 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-07-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 113 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-07-14 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 2026-07-14 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.4 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2026-07-14 | Magnesium [Mass/volume] in Serum or Plasma | 1.7 mg/dL Reference 1.7-2.2 mg/dL |
http://loinc.org · 19123-9 |
| S | 2026-07-14 | Cancer Ag 125 [Units/volume] in Serum or Plasma | 21 U/mL Reference <=35 U/mL |
http://loinc.org · 10334-1 |
| S | 2026-07-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | http://loinc.org · 44261-6 |
| S | 2026-09-15 | Hemoglobin [Mass/volume] in Blood | 11.2 g/dL (low) Reference 11.6-15 g/dL |
http://loinc.org · 718-7 |
| S | 2026-09-15 | Leukocytes [#/volume] in Blood by Automated count | 4.8 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-09-15 | Neutrophils [#/volume] in Blood by Automated count | 2.6 10*3/uL Reference 1.5-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 2026-09-15 | Platelets [#/volume] in Blood by Automated count | 214 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-09-15 | Creatinine [Mass/volume] in Serum or Plasma | 0.69 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-09-15 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 113 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-09-15 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 19 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 2026-09-15 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.4 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2026-09-15 | Cancer Ag 125 [Units/volume] in Serum or Plasma | 9 U/mL Reference <=35 U/mL |
http://loinc.org · 10334-1 |
| S | 2026-09-15 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | http://loinc.org · 44261-6 |
| S | 2026-10-13 | Hemoglobin [Mass/volume] in Blood | 10.6 g/dL (low) Reference 11.6-15 g/dL |
http://loinc.org · 718-7 |
| S | 2026-10-13 | Leukocytes [#/volume] in Blood by Automated count | 4.2 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-10-13 | Neutrophils [#/volume] in Blood by Automated count | 2.4 10*3/uL Reference 1.5-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 2026-10-13 | Platelets [#/volume] in Blood by Automated count | 182 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-10-13 | Cholesterol [Mass/volume] in Serum or Plasma | 186 mg/dL Reference <=200 mg/dL |
http://loinc.org · 2093-3 |
| S | 2026-10-13 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 58 mg/dL Reference >=50 mg/dL |
http://loinc.org · 2085-9 |
| S | 2026-10-13 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 108 mg/dL Reference <=129 mg/dL |
http://loinc.org · 13457-7 |
| S | 2026-10-13 | Triglyceride [Mass/volume] in Serum or Plasma | 98 mg/dL Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 2026-10-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | http://loinc.org · 44261-6 |
| S | 2026-10-13 | Total score [AUDIT-C] | 1 | http://loinc.org · 75626-2 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2026-04-06 | Body height | 160 cm | 8302-2 | S |
| 2026-04-06 | Body weight | 58.5 kg | 29463-7 | S |
| 2026-04-06 | Body mass index (BMI) [Ratio] | 22.9 kg/m2 | 39156-5 | S |
| 2026-04-06 | Systolic blood pressure | 118 mm[Hg] | 8480-6 | S |
| 2026-04-06 | Diastolic blood pressure | 74 mm[Hg] | 8462-4 | S |
| 2026-04-06 | Heart rate | 92 /min | 8867-4 | S |
| 2026-04-06 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-04-06 | Body temperature | 36.9 Cel | 8310-5 | S |
| 2026-04-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-04-14 | Body height | 160 cm | 8302-2 | S |
| 2026-04-14 | Body weight | 58.9 kg | 29463-7 | S |
| 2026-04-14 | Body mass index (BMI) [Ratio] | 23 kg/m2 | 39156-5 | S |
| 2026-04-14 | Systolic blood pressure | 122 mm[Hg] | 8480-6 | S |
| 2026-04-14 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-04-14 | Heart rate | 96 /min | 8867-4 | S |
| 2026-04-14 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-04-14 | Body temperature | 36.8 Cel | 8310-5 | S |
| 2026-04-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-05-12 | Body height | 160 cm | 8302-2 | S |
| 2026-05-12 | Body weight | 55.2 kg | 29463-7 | S |
| 2026-05-12 | Body mass index (BMI) [Ratio] | 21.6 kg/m2 | 39156-5 | S |
| 2026-05-12 | Systolic blood pressure | 112 mm[Hg] | 8480-6 | S |
| 2026-05-12 | Diastolic blood pressure | 70 mm[Hg] | 8462-4 | S |
| 2026-05-12 | Heart rate | 84 /min | 8867-4 | S |
| 2026-05-12 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-05-12 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-05-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-07-14 | Body height | 160 cm | 8302-2 | S |
| 2026-07-14 | Body weight | 55.9 kg | 29463-7 | S |
| 2026-07-14 | Body mass index (BMI) [Ratio] | 21.8 kg/m2 | 39156-5 | S |
| 2026-07-14 | Systolic blood pressure | 110 mm[Hg] | 8480-6 | S |
| 2026-07-14 | Diastolic blood pressure | 70 mm[Hg] | 8462-4 | S |
| 2026-07-14 | Heart rate | 80 /min | 8867-4 | S |
| 2026-07-14 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-07-14 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-07-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-09-15 | Body height | 160 cm | 8302-2 | S |
| 2026-09-15 | Body weight | 56.8 kg | 29463-7 | S |
| 2026-09-15 | Body mass index (BMI) [Ratio] | 22.2 kg/m2 | 39156-5 | S |
| 2026-09-15 | Systolic blood pressure | 114 mm[Hg] | 8480-6 | S |
| 2026-09-15 | Diastolic blood pressure | 72 mm[Hg] | 8462-4 | S |
| 2026-09-15 | Heart rate | 76 /min | 8867-4 | S |
| 2026-09-15 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-09-15 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-09-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-06-09 | Body height | 160 cm | 8302-2 | S |
| 2026-06-09 | Body weight | 55.8 kg | 29463-7 | S |
| 2026-06-09 | Body mass index (BMI) [Ratio] | 21.8 kg/m2 | 39156-5 | S |
| 2026-06-09 | Systolic blood pressure | 108 mm[Hg] | 8480-6 | S |
| 2026-06-09 | Diastolic blood pressure | 68 mm[Hg] | 8462-4 | S |
| 2026-06-09 | Heart rate | 88 /min | 8867-4 | S |
| 2026-06-09 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-06-09 | Body temperature | 37.5 Cel | 8310-5 | S |
| 2026-06-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-10-13 | Body height | 160 cm | 8302-2 | S |
| 2026-10-13 | Body weight | 57.2 kg | 29463-7 | S |
| 2026-10-13 | Body mass index (BMI) [Ratio] | 22.3 kg/m2 | 39156-5 | S |
| 2026-10-13 | Systolic blood pressure | 112 mm[Hg] | 8480-6 | S |
| 2026-10-13 | Diastolic blood pressure | 70 mm[Hg] | 8462-4 | S |
| 2026-10-13 | Heart rate | 74 /min | 8867-4 | S |
| 2026-10-13 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-10-13 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-10-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Comedian and actor; works on film and television; has kept working through her symptoms and worried that she was being dismissed as tired or anxious
- S Married; lives with her spouse. Ashkenazi Jewish ancestry
- S Reproductive history: two early pregnancy losses and one unsuccessful in vitro fertilization cycle; has never carried a pregnancy to term (G2 P0); not trying to conceive now. Periods regular; last period two weeks ago
- S Never smoker; one or two glasses of wine a week; no drugs
- S Supports: her spouse and close friends from work; humor is how she copes. She decides who is told about her health
Functional status
- S Independent; working, but tired by the afternoon and eating smaller meals because she fills up quickly
Mental status
- S Alert, articulate and funny even when worried; organized; asks directly whether this could be cancer
- S Worried and tired; PHQ-2 negative; no thoughts of self-harm
Allergies and medications
Allergies
- S No known allergy
Medications
- S Enoxaparin 40 mg/0.4 mL prefilled syringe, 40 mg under the skin once daily for 28 days after surgery
- S Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain after surgery, no more than 3 g a day
- S Carboplatin 10 mg/mL injection, 610 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cycles
- S Paclitaxel 6 mg/mL injection, 275 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidine
- S Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea
- S Olaparib 150 mg oral tablet, two tablets (300 mg) by mouth twice daily with food, as maintenance for up to two years
Procedures and immunizations
Procedures
- S Transvaginal ultrasound of the pelvis: a 9.2 cm solid and cystic right adnexal mass and a 5.1 cm solid left adnexal mass, both with irregular solid parts and strong internal blood flow; moderate ascites; uterus normal (O-RADS 5)
- S CT of the chest, abdomen and pelvis with contrast: bilateral adnexal masses, moderate ascites, omental caking up to 4 cm, a 1.2 cm nodule on the right hemidiaphragm, and small pelvic peritoneal nodules; no enlarged lymph nodes, no liver or lung lesion, and no pleural effusion
- S Ultrasound-guided core needle biopsy of the omentum: high-grade serous carcinoma, PAX8 and WT1 positive, p53 aberrant (Mullerian origin); CK7 positive, CK20 negative
- S Primary cytoreductive surgery by gynecologic oncology: laparotomy, total abdominal hysterectomy with bilateral salpingo-oophorectomy, total omentectomy, stripping of the right hemidiaphragm peritoneum, and excision of pelvic peritoneal nodules, with no visible residual disease (complete gross resection); lymph nodes not removed because none were enlarged. Pathology: high-grade serous carcinoma of both ovaries with serous tubal intraepithelial carcinoma in the right fallopian tube; omental deposit 4.5 cm, diaphragm 1.3 cm; ascitic fluid positive; pT3c, FIGO stage IIIC
- S Genetic counseling before germline testing: three-generation pedigree, Ashkenazi Jewish ancestry, the meaning of positive, negative and uncertain results for her and for her blood relatives, and consent for a multigene panel
- S Advance care planning conversation, about 20 minutes
- S CT of the chest, abdomen and pelvis with contrast at the end of chemotherapy: no ascites, no peritoneal or omental nodule, no enlarged lymph node, and no liver or lung lesion; expected postoperative changes (no evidence of disease)
Immunizations
- S 2021-09-20: Tdap vaccine
- S 2026-10-13: Influenza vaccine, this season (inactivated)
- S 2026-10-13: COVID-19 mRNA vaccine, this season's formula
- S 2026-10-13: Pneumococcal conjugate vaccine (PCV20)
- S 2026-10-13: Recombinant zoster vaccine, dose 1 of 2
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D 1975 to 1980: Bulimia during her television career in the late 1970s, which she later wrote about; no treatment recorded in the cited source (CLM-0008)
- D About 1985: Two miscarriages and an unsuccessful round of in vitro fertilization in her late thirties (CLM-0007)
Family history
- D father: Brain cancer; died when she was fourteen
- D grandmother: Ovarian cancer; side of the family not recorded in the cited source
- D aunt: Ovarian cancer; side of the family not recorded in the cited source
- D cousin: Ovarian cancer; side of the family not recorded in the cited source
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Tissue diagnosis and gynecologic oncology plan within two weeks of presentation | 2026-04-14 | completed | Ultrasound, CT and biopsy within four days; diagnosis and consultation on the eighth day |
| Cytoreductive surgery with no visible residual disease within three weeks of diagnosis | 2026-05-12 | completed | Complete gross resection one week after the diagnosis |
| Six cycles of carboplatin and paclitaxel every three weeks without a delay of more than one week | 2026-09-15 | completed | Six cycles completed on schedule; CT shows no evidence of disease and CA-125 is 9 |
| Germline and tumor genetic results available before the maintenance decision | 2026-09-15 | completed | Germline panel negative; tumor BRCA1 pathogenic variant; olaparib started |
| PHQ-9 below 10 throughout treatment, with a peer-support connection | 2026-09-15 | completed | PHQ-9 between 3 and 7; attends a cancer support community group |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Urgent gynecologic oncology consultation for a suspected ovarian cancer, before any surgery, to confirm the diagnosis and plan primary treatment | completed | GL-NCCN-OVARIAN-2026, GL-ACOG-CO716-2017 |
| At the first visit: the ovarian cancer symptom index, an abdominal and pelvic examination, CA-125 with CEA, blood count and chemistry, and a urine pregnancy test; transvaginal ultrasound and CT of the chest, abdomen and pelvis within the week, and image-guided biopsy if the scan shows disease outside the pelvis | completed | GL-GOFF-SI-2007, GL-ACOG-CO716-2017, GL-NCCN-OVARIAN-2026 |
| Genetic counseling and germline multigene panel testing (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 and the Lynch syndrome genes), as for every woman with epithelial ovarian cancer, and tumor testing for BRCA1 and BRCA2 and homologous recombination deficiency on the surgical specimen; if a germline variant is found, a family letter offering cascade testing to blood relatives | completed | GL-ASCO-OVGERM-2020, GL-NCCN-OVARIAN-2026 |
| Primary cytoreductive surgery by gynecologic oncology aiming for no visible residual disease, with enoxaparin for four weeks after the operation | completed | GL-NCCN-OVARIAN-2026, GL-ASCO-VTE-2023 |
| Carboplatin (AUC 5) and paclitaxel 175 mg/m2 every three weeks for six cycles, starting three weeks after surgery, after hepatitis B, hepatitis C and HIV screening; a three-drug antiemetic regimen on each treatment day; blood counts, kidney function and magnesium before each cycle; CA-125 each cycle; and neuropathy checks at every visit | completed | GL-NCCN-OVARIAN-2026, GL-ASCO-ANTIEMETIC-2020, GL-ASCO-CIPN-2020, GL-ASCO-HBV-2020 |
| Olaparib 300 mg twice daily as maintenance for two years after a complete response to platinum chemotherapy, chosen because the tumor carries a BRCA1 pathogenic variant; blood count monthly for the first year, with checks for fatigue, nausea, breathlessness and new cough | completed | GL-ASCO-PARP-2020, GL-NCCN-OVARIAN-2026 |
| Surgical menopause: symptom review at each visit, non-hormonal measures, a discussion of menopausal hormone therapy at the end of treatment, and a baseline bone density scan | completed | GL-NCCN-OVARIAN-2026, GL-SGO-SURV-2017 |
| Distress and depression screening at each visit, plain information, a cancer support community group, and survivorship care after treatment: a visit every three months for two years with examination and CA-125, and imaging only for symptoms or a rising CA-125 | completed | GL-SGO-SURV-2017, GL-NCCN-OVARIAN-2026 |
Planned encounters
- 2026-04-06 — Four weeks of bloating, early fullness and pelvic pain in a woman of 39: symptom index, pelvic examination, CA-125, and same-week imaging (ENC-001)
- 2026-04-14 — Biopsy result: ovarian cancer; gynecologic oncology consultation, genetic counseling, and preparation for surgery (ENC-002)
- 2026-05-12 — Review three weeks after cytoreductive surgery: pathology, genetic results, and the first cycle of chemotherapy (ENC-003)
- 2026-06-09 — Same-day sick visit for a cold during chemotherapy (ENC-006, unscheduled)
- 2026-07-14 — Midpoint of chemotherapy: CA-125, blood counts, neuropathy, and menopausal symptoms (ENC-004)
- 2026-09-15 — End of chemotherapy: CT and CA-125 response, and the start of olaparib maintenance (ENC-005)
- 2026-10-13 — Periodic adult preventive visit after ovarian cancer treatment (ENC-007)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Sick Visit
- Progress note 05 — Focused Visit (Follow-up)
- Progress note 06 — Focused Visit (Care-plan review)
- Progress note 07 — Preventive Visit
- Gynecologic Oncology referral
- Gynecologic Oncology consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Sick Visit (XML)
- Progress note 05 — Focused Visit (Follow-up) (XML)
- Progress note 06 — Focused Visit (Care-plan review) (XML)
- Progress note 07 — Preventive Visit (XML)
- Gynecologic Oncology referral (XML)
- Gynecologic Oncology consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | Most A. Gilda Radner. The Shalvi/Hyman Encyclopedia of Jewish Women | Jewish Women's Archive | biography |
| SRC-0002 | Zakarin J. Gilda Radner and Gene Wilder's Enduring, and Heartbreaking, Love Story | Biography.com | biography |
| SRC-0003 | Micheli R. Inside Gene Wilder and Gilda Radner's Romance (excerpted from LIFE: Gene Wilder 1933-2016) | TIME | other |
| SRC-0004 | Fuster J. Read Gene Wilder's Heartbreaking Essay About Wife Gilda Radner's Death | TheWrap | other |
| SRC-0005 | Our History | Gilda's Club Chicago | other |
| SRC-0006 | About the Familial Ovarian Cancer Registry | Roswell Park Comprehensive Cancer Center | other |
| SRC-0007 | Gilda Radner | Wikipedia | other |
| SRC-0008 | Death of comedian Gilda Radner at 42 (This Week in History) | Jewish Women's Archive | other |
| SRC-0009 | HISTMED Master Roster v3 | The Human Record project | other |
| SRC-0010 | Blevins J. Read This: Gilda Radner's needless death became Gene Wilder's crusade | The A.V. Club | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the diagnostic pathway from the symptom index, primary cytoreductive surgery for stage IIIC disease, the chemotherapy and its monitoring, the negative germline panel with a somatic BRCA1 variant, and olaparib maintenance. |
| provenance review | not_started | Jewish Women's Archive (two pages), Biography.com, TIME (LIFE excerpt), TheWrap, The A.V. Club, Gilda's Club Chicago, Roswell Park, and Wikipedia logged. Her memoir was not read directly; quotations from it are taken from Biography.com and Wikipedia. The family history of ovarian cancer rests on a LIFE excerpt reporting her husband's account. |
| safe messaging review | not_started | The bulimia, the pregnancy losses, her final admission and her death are recorded as history only, marked sensitive, and kept short; no eating-disorder or mental-health diagnosis is coded; no genetic result is attributed to any real relative. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.